Company intelligence / Profile preview
Synerkine Pharma
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
Overview
Synerkine Pharma is developing a new class of cytokine fusion proteins for non-opioid treatment of chronic pain, osteoarthritis, and chemotherapy-induced neuropathy. Lead candidate SK‑01 has shown significant efficacy in preclinical models for chronic pain and has received Orphan Drug Designation in Europe for CRPS. No clinical trials are currently registered on ClinicalTrials.gov as of May 2025; the company remains at the preclinical stage with plans to enter clinical development soon
- Therapeutic areas
- NeurologyRheumatology
- Modalities
- Fusion proteins (biologics)Cytokine-based therapeutics
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Synerkine Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synerkine Pharma.